Notably, increasing doses of α-CD276 prolonged graft survival for 2 weeks (Figure 2C), but were associated with increased mortality due to an earlier onset of GvHD, as confirmed by log-rank trend analysis (p = 0.025) (Figure 2D). This evidence concerns the gene CD276 and graft versus host disease.